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Indomethacin protects permeability barrier from focal
segmental glomerulosclerosis serum
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Indomethacin protects permeability barrier from focal segmen- [3–5]. The reasons for this observed increase are unclear
tal glomerulosclerosis serum. at this time.
Background. Eicosanoids are believed to play a role in the The etiology and pathogenesis of FSGS are unknown.pathophysiology of several models of glomerular disease. The
A role for an etiologic factor in the circulation of somecyclooxygenase inhibitor indomethacin reduces proteinuria in
patients with FSGS has been proposed [6–11]. FSGSpatients with focal segmental glomerulosclerosis (FSGS) or
other glomerular diseases. We have shown that sera of some recurs in approximately 30% of patients who undergo
patients with FSGS significantly increase glomerular albumin renal transplantation, and in those patients who have had
permeability (Palb) in an in vitro assay. a prior recurrence FSGS returns in 80% of subsequent
Methods. To determine the role of eicosanoids in the in-
allografts. We have shown that sera from some patientscreased Palb caused by the FSGS factor, glomeruli were isolated
with primary or recurrent FSGS increase the albuminfrom normal rats, preincubated with indomethacin, then incu-
bated with FSGS serum or normal serum and Palb was calcu- permeability (Palb) of isolated rat glomeruli in an in vitro
lated. To study the direct effect of individual eicosanoids on assay [6].
Palb, glomeruli were incubated with prostaglandin E2, prosta- Nonsteroidal anti-inflammatory drugs (NSAIDs) such
glandin F2 or a thromboxane A2 mimetic, and Palb was calcu- as indomethacin inhibit cyclooxygenase in the arachi-lated. In the final set of experiments, normal glomeruli were
donic acid metabolism pathway. NSAIDs have been usedpreincubated with the thromboxane synthase inhibitor fureg-
relate, incubated with FSGS serum, and Palb was calculated. in the treatment of patients with nephrotic syndrome
Results. Preincubation of isolated glomeruli with either the [12, 13]. A beneficial effect of NSAIDs in reducing pro-
cyclooxygenase inhibitor indomethacin or the thromboxane teinuria in patients with primary or recurrent FSGS has
synthase inhibitor furegrelate protected glomeruli from the
been documented [12–15]. The purpose of these studiesincrease in Palb caused by FSGS serum. Each of the three princi-
was to determine whether the cyclooxygenase inhibitorpal glomerular eicosanoids significantly increased Palb of iso-
lated glomeruli. indomethacin alters the effect of FSGS serum on Palb of
Conclusions. These studies implicate a product of the cyclo- isolated glomeruli. We also sought to determine if one
oxygenase pathway of arachidonic acid metabolism as mediat- or more of the primary arachidonic acid metabolites
ing the increased Palb caused by FSGS serum in our in vitro produced by glomerular cells alter Palb of isolated glo-assay and possibly the proteinuria seen in patients with FSGS.
meruli.
Primary focal segmental glomerulosclerosis (FSGS) is METHODS
a glomerular disease characterized by heavy proteinuria, Experimental animals
hypertension, and frequent progression to renal failure.
Normal male Sprague-Dawley rats (180 to 250 g)It is a major cause of nephrotic syndrome in both children
maintained on Purina rat chow and water ad libitumand adults, and its impact appears to be growing [1, 2].
were used in all experiments. In all cases kidneys wereSeveral investigators have reported an up to eightfold
removed via abdominal incision after the animals wereincrease in the incidence of FSGS over the past 20 years
properly anesthetized using metofane (Pitman Moore
Inc., NJ, USA).
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Isolation of glomeruligenase inhibitor, proteinuria, arachidonic acid.
After removal of the kidney capsule, the outer 1 to 2Received for publication March 9, 2001
mm of renal cortex was excised. Renal cortical slicesand in revised form August 16, 2001
Accepted for publication September 28, 2001 were cut into fine fragments and the fragments were
passed through consecutive screens of 80, 120 and 200 2002 by the International Society of Nephrology
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mesh size [16]. Glomeruli were recovered from atop the Effect of individual eicosanoids. Glomeruli were iso-
lated from normal rats as described above, and then200 mesh screen. Isolation of glomeruli was carried out
at room temperature in medium which contained, in incubated with various concentrations of prostaglandin
E2 (0.1, 0.5, 1.0, 5.0, 50 or 100 nmol/L), prostaglandinmmol/L: sodium chloride, 115; potassium chloride, 5;
sodium acetate, 10; dibasic sodium phosphate, 1.2; so- F2 (0.5, 1.0, 5.0, 10, 20, 50 or 100 nmol/L) or the throm-
boxane A2 mimetic U46619 (1.0, 5.0, 10 or 100 mol/L)dium bicarbonate, 25; magnesium sulfate, 1.2; calcium
chloride, 1; glucose, 5.5; l-alanine, 6; sodium citrate, 1; for 10 minutes at 37C. These concentrations were cho-
sen as they are well within the ranges that have beensodium lactate, 4. Bovine serum albumin (BSA) 4 g/dL
was included in the medium as an oncotic agent. The shown by other investigators to effect changes in glomer-
ular cells [20–25]. In each set of experiments glomerulipH of the medium was adjusted to 7.4. The oncotic pres-
sure was measured using a membrane colloid osmometer were also incubated with FSGS or normal human serum
as the positive or negative control, respectively.(Model 4100; Wescor Inc., Logan, UT, USA).
Effect of furegrelate. Glomeruli were preincubated
FSGS serum with various concentrations of the thromboxane synthase
inhibitor furegrelate (0.04, 0.08, 0.2 or 0.4 mol/L) forSerum from a patient who experienced a rapid recur-
rence of FSGS in a renal allograft was used in most 30 minutes at 37C, washed with fresh medium, then
incubated with either FSGS serum or normal serum forexperiments. This patient’s serum has shown a consis-
tently high level of activity (that is, the capacity to in- 10 minutes at 37C prior to determination of Palb. These
concentrations of furegrelate were chosen as they arecrease Palb) in our in vitro assay, and has been used
extensively as a positive control. Serum from each of four within the range shown by other investigators to inhibit
physiologic effects caused by thromboxane A2 [26–28].additional patients with FSGS also was used in further
studies. In all experiments 1:50 dilution of FSGS serum
Measurement of glomerular volume response (V)(positive control) or serum from normal volunteers (neg-
ative control) was used. The volume response of glomerular capillaries to an
oncotic gradient was measured in the following manner
Chemicals [16]. Glomeruli were incubated in isolation medium con-
taining normal serum, FSGS serum or various concentra-Indomethacin and sodium furegrelate were obtained
from Biomol Research Laboratories (Plymouth Meet- tions of prostaglandin E2, prostaglandin F2 or the throm-
boxane A2 mimetic U46619 for 10 minutes at 37C. Ining, PA, USA). Prostaglandin E2, prostaglandin F2, and
the thromboxane A2 mimetic U46619 were obtained some experiments glomeruli were preincubated with var-
ious concentrations of indomethacin or furegrelate asfrom Cayman Chemical (Ann Arbor, MI, USA). All
other chemicals including 35% BSA solution were ob- noted above. Glomeruli were then affixed to a glass
coverslip coated with poly-l-lysine (1 mg/mL) and ob-tained from Sigma Chemical (St. Louis, MO, USA).
served using videomicroscopy before and two to three
Treatment of glomeruli minutes after the medium containing 4 g/dL BSA was
replaced by medium containing 1 g/dL BSA. This ex-Effect of indomethacin. In the first set of experiments,
isolated glomeruli were preincubated with indomethacin change of medium produced an oncotic gradient across
the glomerular capillary wall and resulted in net fluidat various concentrations (0.002, 0.01, 0.02, 1.0, 2.0, or
5.0mol/L) for 30 minutes at 37C. These concentrations influx and an increase in glomerular volume. Glomerular
volume was calculated from the average of four diame-of indomethacin were chosen, as they are consistent with
those that have been shown by other investigators to ters of the video image and the increase in volume (V)
of each glomerulus in response to an oncotic gradientinhibit cyclooxygenase-mediated physiologic responses
in glomeruli or glomerular cells [17–20]. FSGS serum or was expressed as: V  (Vinitial  Vfinal)/Vinitial  100%
normal serum was then added, and glomeruli incubated
Reflection coefficient of albumin (alb)for an additional 10 minutes at 37C. In some experi-
ments glomeruli were washed three times after preincu- There is a direct relationship between the increase in
glomerular volume (V) and the oncotic gradient ()bation with indomethacin with fresh isolation medium
that contained no indomethacin, and then incubated with applied across the capillary wall [16]. This principle was
used to calculate 	alb, using the ratio ofV of experimen-FSGS or normal serum. Palb was then determined using
volumetric change after bathing medium was changed tal to V of control glomeruli in response to identical
oncotic gradients: 	alb  Vexperimental/Vcontrolto one of lower oncotic pressure (see below). In order
to demonstrate that any observed effect was not re-
Convectional permeability to albuminstricted to the serum of a single patient, the experiment
was repeated using serum from each of four additional Convectional albumin permeability (Palb) was defined
as (1 	alb) to describe the movement of albumin conse-patients.
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Fig. 1. Effect of indomethacin on increased
albumin permeability (Palb) caused by focal
segmental glomerulosclerosis (FSGS) serum.
Glomeruli were preincubated with indometh-
acin then incubated with FSGS serum and
Palb was determined. FSGS serum (N  37)
significantly increased Palb compared to nor-
mal serum (N  32). Indomethacin (0.002
mol/L, N  7; 0.01 mol/L, N  6; 0.02
mol/L, N  14; 1 mol/L, N  14; 2 mol/L,
N  6; and 5 mol/L N  12) protected the
permeability barrier from the effect of FSGS
serum (*P 
 0.01 compared to FSGS serum,
**P 
 0.001 compared to FSGS serum).
quent to water flow [16]. When 	alb is zero, albumin patients with FSGS. Indomethacin protected Palb from
the effect of FSGS serum (FSGS patient sera 0.77  0.06,moves at the same rate as water and Palb is 1.0. Alterna-
tively, when 	alb is 1.0, albumin cannot cross the mem- N  23 vs. preincubation with indomethacin 0.10 
0.08, N  17, P 
 0.01).brane with water and Palb is zero.
Statistical analysis Incubation with prostaglandin E2 increases Palb
Prostaglandin E2 significantly increased Palb of isolatedAlbumin permeability values are expressed as mean
SEM. N represents the number of glomeruli studied. glomeruli compared to normal serum (Fig. 2). This effect
was seen at concentrations of prostaglandin E2 as low asValues among various groups were compared using
ANOVA. Significance was defined as P 
 0.05. 0.5 nmol/L. The increase in Palb caused by prostaglandin
E2 at concentrations of 5.0 nmol/L or greater was compa-
rable to the increase caused by FSGS serum.
RESULTS
Incubation with prostaglandin F2 increases PalbIndomethacin protects glomeruli from increase in Palb
caused by FSGS serum Prostaglandin F2 significantly increased Palb of isolated
glomeruli compared to normal serum (Fig. 3). This effectPreincubation with indomethacin protected glomeruli
was seen at concentrations of prostaglandin F2 as lowfrom the increase in Palb caused by FSGS serum. Palb of
as 5 nmol/L. The increase in Palb caused by prostaglandinglomeruli preincubated with indomethacin was signifi-
F2 at concentrations of 5.0 nmol/L or greater was compa-cantly different from that of glomeruli incubated only
rable to the increase caused by FSGS serum.with FSGS serum (positive control), and this difference
was seen at all concentrations of indomethacin tested
Incubation with U46619 increases Palb(Fig. 1). There was a trend toward greater protection
The thromboxane A2 mimetic U46619 significantly in-at higher concentrations of indomethacin. In order to
creased Palb of isolated glomeruli compared to normaleliminate the possibility of a direct interaction between
serum (Fig. 4). This effect was seen at concentrations ofindomethacin and a substance in FSGS serum, glomer-
U46619 as low as 5.0 mol/L. The increase in Palb causeduli that had been preincubated with indomethacin (5
by the thromboxane A2 mimetic at concentrations of 5.0mol/L) were washed with fresh medium that contained
mol/L or greater was comparable to the increase causedno indomethacin, then incubated with FSGS or normal
by FSGS serum.serum. This treatment conferred a comparable degree
of protection from the increase in Palb caused by FSGS
Furegrelate protects glomeruli from increase in Palbserum (FSGS serum 0.80  0.04, N  12; unwashed
glomeruli 0.15  0.01, N  12; washed glomeruli 0.27  Preincubation with the thromboxane synthase inhibi-
tor furegrelate protected isolated glomeruli from the in-0.06 N  9), with Palb of both indomethacin treatments
different from FSGS serum (P 
 0.01). crease in Palb caused by FSGS serum (Fig. 5). Palb was
significantly different from that caused by FSGS serum atTo rule out the possibility that the glomerular response
was specific to one patient’s serum, isolated glomeruli all concentrations tested. Furthermore, Palb of glomeruli
preincubated with furegrelate at a concentration of 0.4were preincubated with indomethacin (1 mol/L) and
then incubated with serum from each of four additional mol/L was not different from negative control.
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Fig. 2. Effect of prostaglandin E2 (PGE2) on
Palb. Glomeruli were incubated with various
concentrations of prostaglandin E2 and Palb
was determined. FSGS serum (N  15) sig-
nificantly increased Palb compared to normal
serum (N  17). Prostaglandin E2 increased
Palb compared to control at concentrations of
0.5 nmol/L (N  12), 1 nmol/L (N  8),
5 nmol/L (N  9), 50 nmol/L (N  9) or
100 nmol/L (N  15). Palb at concentrations
of 0.01 nmol/L (N  11) or 0.1 nmol/L (N 
11) was not different from control (*P
 0.001
compared to normal serum).
Fig. 3. Effect of prostaglandin F2 (PGF2) on
Palb. Glomeruli were incubated with various
concentrations of prostaglandin F2 and Palb
was determined. FSGS serum (N  9) in-
creased Palb compared to normal serum (N 
10). Prostaglandin F2 increased Palb compared
to control at concentrations of 5 nmol/L (N 
11), 10 nmol/L (N  11), 20 nmol/L (N  12),
50 nmol/L (N  17) or 100 nmol/L (N  9).
Palb at concentrations of 0.5 nmol/L (N  12)
or 1 nmol/L (N  11) was not different from
control (*P 
 0.001 compared to normal
serum).
Fig. 4. Effect of the thromboxane A2 (TXA2)
mimetic U46619 on Palb. Glomeruli were incu-
bated with various concentrations of U46619
and Palb was determined. FSGS serum (N 
34) increased Palb compared to normal serum
(N  34). The thromboxane A2 mimetic
U46619 increased Palb at concentrations of 5
mol/L (N  33), 10 mol/L (N  9) or 100
mol/L (N  10) compared to control. Palb at
concentrations of at 1 mol/L (N  10) was
not different from control (*P 
 0.001 com-
pared to normal serum).
To rule out the possibility that the glomerular response DISCUSSION
was specific to one patient’s serum, isolated glomeruli These results show that the cyclooxygenase inhibitor
were preincubated with furegrelate (0.2 mol/L) and indomethacin provides protection against the increased
then incubated with serum from each of four additional Palb caused by FSGS serum in our in vitro assay. Addi-
patients with FSGS. Furegrelate protected Palb from the tionally, we have demonstrated that incubation with any
effect of FSGS serum (FSGS patient sera 0.77  0.06, of the major glomerular eicosanoids, that is, prostaglan-
N  23 vs. preincubation with furegrelate 0.11  0.01, din E2, prostaglandin F2 or the thromboxane A2 mimetic
U46619, increases Palb of isolated glomeruli. The throm-N  20, P 
 0.01).
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Fig. 5. Effect of furegrelate on increased Palb
caused by FSGS serum. Glomeruli were prein-
cubated with the thromboxane synthase inhib-
itor furegrelate then incubated with FSGS se-
rum and Palb was determined. FSGS serum
(N 20) increased Palb significantly compared
to normal serum (N  19). Furegrelate (0.04
mol/L, N  5; 0.08 mol/L, N  5; 0.2
mol/L, N  5 or 0.4 mol/L, N  19) pro-
tected the permeability barrier from FSGS
serum (*P
 0.001 compared to FSGS serum).
boxane synthase inhibitor furegrelate also protects glo- in and Cook showed that indomethacin significantly re-
duced the fractional clearance of neutral dextrans in ameruli from the increase in Palb caused by the FSGS
factor. model of nephrotoxic serum nephritis [40]. The investi-
gators theorized that indomethacin reduced the contri-Nonsteroidal anti-inflammatory drugs (NSAIDs) have
been reported for over 30 years to reduce proteinuria in bution of nonselective shunt pathways through which
proteins leak out of glomerular capillaries. Golbetz etpatients with glomerular diseases [12, 13]. Investigators
have described a reduction in proteinuria in nephrotic al treated nephrotic patients with indomethacin, and
found a significant reduction in glomerular filtration ratepatients treated with NSAIDs, such as indomethacin
(12–14, 29–31) or other NSAIDs [31–33]. This effect has (GFR) and renal plasma flow (RPF) after three days of
treatment [44]. Additionally, indomethacin significantlybeen seen with both acute and chronic use of these drugs.
As a rule, proteinuria reaches pretreatment levels with decreased the fractional clearance of large dextrans. Al-
lon, Pasque and Rodriguez concluded that addition ofcessation of the NSAID.
NSAIDs have been used clinically to treat proteinuria the NSAID ibuprofen enhanced the antiproteinuric ef-
fect of captopril not only by decreasing GFR, but alsoseen in a variety of conditions. The beneficial effect of
NSAIDs has been noted in primary [12, 13, 29–32] and by enhancing permselectivity of the glomerular perme-
ability barrier [45]. It has been noted by several investiga-recurrent FSGS [14, 15]. NSAIDs have been used to treat
other glomerular diseases with a measure of success, tors that though treatment with indomethacin decreased
GFR, the proportional decrease in proteinuria was sig-including lupus nephritis [34], IgA nephropathy [35], mem-
branous glomerulopathy [36, 37], and exercise-induced pro- nificantly greater that the decrease in GFR [37]. More-
over, the beneficial effect on proteinuria persists despiteteinuria [38].
Several investigators have examined the mechanism recovery in GFR [46, 47]. Together these studies support
the notion that NSAIDs, indomethacin in particular, mayby which indomethacin and other NSAIDs reduce pro-
teinuria. It has been generally held that cyclooxygenase alter the intrinsic properties of the glomerular protein
permeability barrier.inhibition alters relative and absolute levels of renal eico-
sanoids, which in turn leads to change in glomerular Glomerular cells synthesize eicosanoids in health and
disease. The major eicosanoids produced by glomerularhemodynamics, specifically tone of the glomerular vascu-
lature [12, 13]. Investigators have shown in animal mod- epithelial, glomerular endothelial or mesangial cells are
prostaglandin E2, prostaglandin F2 and thromboxaneels of renal disease that inhibition of eicosanoid produc-
tion with the cyclooxygenase inhibitor indomethacin A2 [48–52]. Products of arachidonic acid metabolism,
including those of the cyclooxygenase pathway, haveleads to a decrease in vasodilatory eicosanoids and subse-
quent increase in both afferent and efferent arteriolar been implicated in proteinuria seen in experimental glo-
merular disease. Remuzzi et al demonstrated that iso-tone [39–41]. It is proposed that in humans the reduction
in glomerular filtration rate and intraglomerular pressure lated glomeruli from rats made nephrotic after a single
dose of the glomerular epithelial cell toxin adriamycinact to decrease proteinuria [42, 43].
In addition to its effects on hemodynamics, there is generated significantly more thromboxane B2 (the stable
metabolite of thromboxane A2) than normal glomerulievidence that indomethacin alters the properties of the
glomerular protein permeability barrier. Neugarten, Koz- [53]. Urinary excretion of thromboxane B2 was increased
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in nephrotic animals, and treatment of animals with a is unlikely that the structure of the glomerular basement
membrane was substantially altered as a result of onlythromboxane synthase inhibitor decreased both protein-
uria and urinary excretion of thromboxane B2. Lianos, brief in vitro exposure to indomethacin. Likewise, the
hemodynamic or other systemic effects of furegrelateAndres and Dunn showed that isolated glomeruli from
a model of nephrotoxic nephritis had a marked increase are obviated by using isolated glomeruli. Preincubation
with indomethacin or furegrelate prevented the increasein thromboxane synthesis [54]. This increased synthesis
was correlated with the degree of proteinuria. Alavi et in Palb caused by serum from each of four additional
patients with recurrent FSGS, which demonstrates thatal and Vriesendorp et al demonstrated a correlation be-
tween decrement in proteinuria and prostaglandin E2 the protection conferred by these drugs is not specific
to a particular patient’s serum.excretion in nephrotic patients treated with NSAIDs,
including indomethacin [37, 55]. We further demonstrate that each of the primary glo-
merular eicosanoids can increase glomerular albuminIndomethacin was shown to reduce proteinuria in pas-
sive Heymann nephritis without altering inulin clearance permeability and that this effect is once again indepen-
dent of humoral or hemodynamic factors. The concentra-[56]. Cybulsky et al demonstrated that indomethacin de-
creased proteinuria and urinary prostaglandin E2 excre- tions of the thromboxane A2 mimetic U46619 that are
required to cause increased Palb are higher than those oftion in a rat model of membranous glomerulopathy [57].
This group found that treatment with a thromboxane either prostaglandin E2 or prostaglandin F2, though are
well within the range of concentrations that have beensynthase inhibitor decreased proteinuria in these rats as
well. Cybulsky et al then demonstrated that glomerular demonstrated to alter glomerular physiology [23–25].
Thromboxane A2 is a highly labile compound comparedepithelial cells in culture release increased amounts of
prostaglandin F2 and thromboxane A2 when incubated with its stable mimetic U46619. U46619 differs chemi-
cally from native thromboxane A2 in its ring structure.with anti-Fx1a antibodies and complement [58]. Eicosa-
noids are implicated as important mediators of protein- It is possible that this mimetic is relatively less active in
our in vitro assay that the native compound. Alterna-uria seen in other models of noninflammatory glomerular
diseases, such as the remnant kidney model [59–63], pro- tively, it is possible that thromboxane A2 itself has less
teinuria seen with high protein diet [64, 65] and exercise- effect on the albumin permeability barrier than the other
induced proteinuria [66]. The central role played by eico- eicosanoids tested. However, the finding that inhibition
sanoids, in particular thromboxane A2, in anti-Thy-1 im- of thromboxane synthase with furegrelate protects the
mune injury has been demonstrated by several groups permeability barrier from increased Palb caused by the
[67–69]. FSGS factor strengthens the conclusion that thrombox-
We have demonstrated the presence of a substance in ane A2 may play an important role in the increased Palb.
the plasma or serum (FSGS factor) of some patients It is possible that one or more of the major eicosanoids
with primary or recurrent FSGS that increases albumin produced by glomerular cells are critical to mediate the
permeability of isolated glomeruli in a unique bioassay. increased Palb seen in vitro.
Presence of this FSGS factor is associated with and pre- We theorize that a factor present in the serum of some
dictive of recurrence of disease in renal allografts [6]. patients with FSGS may alter eicosanoid production of
The causative substance appears to be of low molecular one or more glomerular cell types, leading to changes
weight, and we have succeeded in enriching this factor in the metabolism and function of cells of the filtration
more than a hundred-fold [70]. The mechanism by which barrier. Inhibition of either cyclooxygenase or throm-
this FSGS factor alters the protein permeability barrier boxane synthase appears to prevent or possibly offset
of the glomerulus is unknown, nor is it known which the change in eicosanoid metabolism caused by FSGS
cell(s) of the glomerulus is affected by the FSGS factor. serum. Further studies are needed to understand the role
In light of the existing body of evidence that eicosa- played by various arachidonic acid metabolites in the
noids alter glomerular physiology, we sought to deter- increased Palb seen in vitro and proteinuria in the clinical
mine if these substances are responsible for the increased setting. Greater understanding of arachidonic acid me-
glomerular permeability caused by the FSGS factor. Our tabolism in FSGS may lead to more effective treatment
results implicate a product of the cyclooxygenase path- strategies.
way of arachidonic acid metabolism as a crucial mediator
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